Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Current factor IX (FIX) products display a half-life (t(1/2)) of ∼ 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in patients with hemophilia B. This open-label, dose-escalation trial in previously treated adult subjects with hemophilia B examined the safety and pha...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Shapiro, Amy D., Ragni, Margaret V., Valentino, Leonard A., Key, Nigel S., Josephson, Neil C., Powell, Jerry S., Cheng, Gregory, Thompson, Arthur R., Goyal, Jaya, Tubridy, Karen L., Peters, Robert T., Dumont, Jennifer A., Euwart, Donald, Li, Lian, Hallén, Bengt, Gozzi, Peter, Bitonti, Alan J., Jiang, Haiyan, Luk, Alvin, Pierce, Glenn F.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2012
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3265197/
https://ncbi.nlm.nih.gov/pubmed/22110246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-367003
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים